Dosage: 750 mg (from 1000mg Safflower Oil)
Size: 90 Softgels
• Contains Conjugated Linoleic Acid
• May Help in Reducing Body Fat
• Helps Support Immune System
• May Help in Reducing Food Induced Allergic Reactions
CLA contains Conjugated Linoleic Acid (CLA), a unique optical isomer of the polyunsaturated fatty acid linoleic acid. CLA is a lipid component of cell membranes and breast milk. Although dietary sources of CLA typically include red meat and dairy products, Jarrow FORMULAS CLA 750 is derived from safflower oil. Two CLA 750 softgels offer the CLA equivalent of what is found in 38 slices of cheese. CLA has been shown in animal experiments to assist in glucose metabolism, body fat reduction and enhancement/retention of lean body mass (muscle).
Suggested Use: Take 3 to 4 softgels per day with meals, or as directed by your qualified health care consultant. Pregnant or lactating women should consult a physician before taking CLA. Store in a cool dry place.
SUPPLEMENT FACTS
Serving Size: 1 Softgel
Servings Per Container: 90
Amount Per Serving / %DV
Calories – 10 Kcal / *
Total Fat – 1g / 2%
(750mg Conjugated Linoleic Acid, a polyunsaturated fat 18:2,
from 1,000mg Safflower Oil containing a minimum of 75-82% CLA)
Conjugated Linoleic Acid – 750mg / *
Safflower Oil Base – 250mg / *
*Daily Value (DV) not established.
Other Ingredients: Mixed tocopherols. Softgel consists of gelatin, glycerin, water and natural caramel color (added as a light barrier).
No wheat, no gluten, no soybeans, no dairy, no egg, no fish/shellfish, no peanuts/tree nuts.
1. Devery R, Miller A, Stanton C. Conjugated linoleic acid and oxidative behaviour in cancer cells.
Biochem Soc Trans. 2001 Apr;29(2):341-4.
2. Liew C, Schut HA, Chin SF, Pariza MW, Dashwood RH. Protection of conjugated linoleic acids against 2-amino-
3- methylimidazo[4,5-f] quinoline-induced colon carcino- genesis in the F344 rat: a study of inhibitory mechanisms.
Carcinogenesis. 1995 Dec;16(12):3037-43.
3. Pariza MW, Park Y, Cook ME. Conjugated linoleic acid and the control of cancer and obesity. Toxicol Sci. 1999 Dec;52(2 Suppl):107-10.
4. Pariza MW, et al. Formation and action of anticarcinogenic fatty acids. Adv Exp Med Biol. 1991;289:269-72.
5. Ringbom T, Huss U, Stenholm A, Flock S, Skattebol L, Perera P, Bohlin L. Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9. .
Image and text supplied courtesy of Jarrow FORMULAS, all rights reserved.
